Загрузка...
Orlistat, a New Lipase Inhibitor for the Management of Obesity
Orlistat, a weight-loss agent with a novel mechanism of action, recently was approved by the Food and Drug Administration for the treatment of obesity. It inhibits gastric and pancreatic lipases in the lumen of the gastrointestinal tract to decrease systemic absorption of dietary fat. In several tri...
Сохранить в:
| Опубликовано в: : | Pharmacotherapy |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2000
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6145169/ https://ncbi.nlm.nih.gov/pubmed/10730683 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|